<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="353">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156554</url>
  </required_header>
  <id_info>
    <org_study_id>MA-ASCT-II-001</org_study_id>
    <nct_id>NCT05156554</nct_id>
  </id_info>
  <brief_title>PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>A Multicenter Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF Compared With rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF compared with&#xD;
      rhG-CSF on the recovery of hematopoietic function after autologous stem cell transplantation&#xD;
      in patients with lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF compared with&#xD;
      rhG-CSF in lymphoma patients after autologous hematopoietic stem cell transplantation.&#xD;
      Eligible patients were randomly assigned to PEG-rhG-CSF group or rhG-CSF group. Patients in&#xD;
      PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation with a dose of 6 mg.&#xD;
      Patients in rhG-CSF group received rhG-CSF day +1 after transplantation with a dose of 5μg/kg&#xD;
      once per day until the count of neutrophil&gt;0.5×10^9 /L.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of neutrophilic granulocytopenia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutrophilic granulocytopenia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet engraftment and number of platelet transfused to the patient</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>30 days</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in PEG-rhG-CSF group received PEG-rhG-CSF day+1 after transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhG-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in rhG-CSF group received rhG-CSF day+1 after transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <description>PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.</description>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF</intervention_name>
    <description>rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 5μg/kg once per day until the count of neutrophil&gt;0.5×10^9 /L.</description>
    <arm_group_label>rhG-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with age between 18 and 65 years;&#xD;
&#xD;
          2. hematopoietic stem cell transplantation for the first time;&#xD;
&#xD;
          3. Lymphoma patients with the requirement for autologous;&#xD;
&#xD;
          4. ECOG score ≤2;&#xD;
&#xD;
          5. Estimated survival time &gt; 3 months;&#xD;
&#xD;
          6. All acute toxicity caused by previous chemotherapy or treatment has been restored;&#xD;
             7.1) The absolute value of neutrophils (&gt;1.5×10^9/L); Hemoglobin (&gt; 90 g/L); 2)Upper&#xD;
             Limit Normal (ULN) or creatinine clearance rate (&gt;40 mL/min) of serum creatinine (&lt;1.5&#xD;
             times normal value upper limit) (estimated by Cockcroft-Gault formula); Serum total&#xD;
             bilirubin &lt; 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase&#xD;
             (ALT) = 2.5 times ULN; 7) Coagulation function: International Normalized Ratio (INR) =&#xD;
             1.5 times ULN; Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) =&#xD;
             1.5 times ULN (unless the subject is receiving anticoagulant therapy and PT and APTT&#xD;
             are using anticoagulant therapy at screening time). Within the expected range;&#xD;
             Thyrotropin (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) were all&#xD;
             within the normal range (+10%);&#xD;
&#xD;
        8.Not in pregnancy; 9.Written informed consent are acquired.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had received autologous hematopoietic stem cell transplantation or allogeneic&#xD;
             transplantation;&#xD;
&#xD;
          2. bone marrow involvement;&#xD;
&#xD;
          3. Patients with active autoimmune diseases requiring systematic treatment were excluded&#xD;
             according to the clinical judgment of the investigators;&#xD;
&#xD;
          4. Patients with active infections requiring systematic treatment were excluded according&#xD;
             to the clinical judgment of the investigators;&#xD;
&#xD;
          5. Serious complications, such as severe infection, heart, lung, liver and kidney&#xD;
             dysfunction；&#xD;
&#xD;
          6. patients in fever of unknown origin before medication（&gt;38℃）；&#xD;
&#xD;
          7. central nervous system involvement;&#xD;
&#xD;
          8. Patients that received pelvic radiotherapy;&#xD;
&#xD;
          9. patients will received Chemotherapy or radiotherapy under the diaphragm after&#xD;
             transplantation ；&#xD;
&#xD;
         10. Participation or consideration of participation in another biomedical study during the&#xD;
             follow-up period of the present trial;&#xD;
&#xD;
         11. Pregnant or lactating women;&#xD;
&#xD;
         12. Serious heart, lung, hemorrhagic disease;&#xD;
&#xD;
         13. Past psychiatric history; incapacitated or restricted;&#xD;
&#xD;
         14. patient's condition increase the risk of receiving the drug treatment or confusion&#xD;
             about the toxic reaction；&#xD;
&#xD;
         15. Severe intolerance to the growth factor under study, or hypersensitivity to one of&#xD;
             their components;&#xD;
&#xD;
         16. the patients did not comply with the study;&#xD;
&#xD;
         17. Other situation that investigators consider as contra-indication for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiqiang Huang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huiqiang Huang, professor</last_name>
    <phone>0086-13808885154</phone>
    <email>huang_sysu@163.com</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 12, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huiqiang Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

